Decrease in Ideal Cardiovascular Health Among American Adults
Despite progress in heart disease, the number of adults achieving ideal cardiovascular health, as defined by the American Heart Association’s Simple 7 health metrics, has decreased.
All articles by John Schieszer, MA
Candesartan May Be Cardioprotective in Women With Breast Cancer Treated with Adjuvant Therapy
Breast cancer patients may benefit from concomitant treatment with candesartan to prevent decline in global left ventricular function.
Left Ventricular Augmentation With Algisyl May Benefit Heart Failure Patients
Algisyl may be more effective when added to standard medical therapy vs standard medical therapy alone for heart failure patients.
High Cholesterol Undertreated in Hispanic Patients
Only one-third to one-half of eligible Hispanic patients studied take statins or other lipid-lowering agents.
Heart Failure Hospitalizations, CV Death Reduced With Empagliflozin
Results from the EMPA-REG OUTCOME trial showed empagliflozin reduced heart failure hospitalizations and cardiovascular deaths in patients with type 2 diabetes.
Risk of Cardiovascular Disease Questioned in Testosterone Therapy Use
The American Association of Clinical Endocrinologists site lack of evidence of cardiovascular disease risk in testosterone therapy use.
Improving Dyslipidemia: Navigating the Guidelines
Dyslipidemia guidelines, and how to incorporate them into clinical practice, were addressed at the American Association of Diabetes Education meeting.
Sitagliptin Does Not Increase Risk for Cardiovascular Events, Heart Failure
Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.
- Loading...
Loading...
Next post in Metabolic
Loading... 
Loading...